Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89744 | 0.90 | REN (0.42) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL89432 | 0.89 | REN (0.40) | RENKMT2AMEN1 | |
| SCHEMBL89957 | 0.89 | REN (0.52) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL89516 | 0.88 | REN (0.42) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL90131 | 0.88 | REN (0.43) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL89822 | 0.87 | REN (0.44) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1911409 | 0.87 | REN (0.44) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL89215 | 0.87 | REN (0.43) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8236774 | 0.87 | REN (0.43) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL90216 | 0.87 | REN (0.43) | RENKMT2AMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | REN 1/4885KMT2A 3129/4885MEN1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.